Advertisement
Advertisement
Advertisement
Advertisement
Von Willebrand disease (vWD) is a bleeding disorder characterized by a qualitative or quantitative deficiency of von Willebrand factor von Willebrand factor A high-molecular-weight plasma protein, produced by endothelial cells and megakaryocytes, that is part of the factor VIII/von Willebrand factor complex. The von Willebrand factor has receptors for collagen, platelets, and ristocetin activity as well as the immunologically distinct antigenic determinants. It functions in adhesion of platelets to collagen and hemostatic plug formation. The prolonged bleeding time in von Willebrand diseases is due to the deficiency of this factor. Hemostasis (vWF). Most cases are hereditary, but acquired forms have been described. Von Willebrand factor von Willebrand factor A high-molecular-weight plasma protein, produced by endothelial cells and megakaryocytes, that is part of the factor VIII/von Willebrand factor complex. The von Willebrand factor has receptors for collagen, platelets, and ristocetin activity as well as the immunologically distinct antigenic determinants. It functions in adhesion of platelets to collagen and hemostatic plug formation. The prolonged bleeding time in von Willebrand diseases is due to the deficiency of this factor. Hemostasis is a multimeric protein involved in the plate adhesion Adhesion The process whereby platelets adhere to something other than platelets, e.g., collagen; basement membrane; microfibrils; or other 'foreign' surfaces. Coagulation Studies phase of hemostasis Hemostasis Hemostasis refers to the innate, stepwise body processes that occur following vessel injury, resulting in clot formation and cessation of bleeding. Hemostasis occurs in 2 phases, namely, primary and secondary. Primary hemostasis involves forming a plug that stops the bleeding temporarily. Secondary hemostasis involves the activation of the coagulation cascade. Hemostasis by forming a bridge between platelets Platelets Platelets are small cell fragments involved in hemostasis. Thrombopoiesis takes place primarily in the bone marrow through a series of cell differentiation and is influenced by several cytokines. Platelets are formed after fragmentation of the megakaryocyte cytoplasm. Platelets: Histology and damaged portions of the vessel wall. Von Willebrand factor von Willebrand factor A high-molecular-weight plasma protein, produced by endothelial cells and megakaryocytes, that is part of the factor VIII/von Willebrand factor complex. The von Willebrand factor has receptors for collagen, platelets, and ristocetin activity as well as the immunologically distinct antigenic determinants. It functions in adhesion of platelets to collagen and hemostatic plug formation. The prolonged bleeding time in von Willebrand diseases is due to the deficiency of this factor. Hemostasis also regulates the levels of coagulation factor VIII Factor VIII Factor VIII of blood coagulation. Antihemophilic factor that is part of the factor viii/von Willebrand factor complex. Factor VIII is produced in the liver and acts in the intrinsic pathway of blood coagulation. It serves as a cofactor in factor X activation and this action is markedly enhanced by small amounts of thrombin. Hemostasis (FVIII) by acting as its carrier Carrier Vaccination. Clinical features vary depending on the plasma Plasma The residual portion of blood that is left after removal of blood cells by centrifugation without prior blood coagulation. Transfusion Products vWF levels. Most cases are asymptomatic, but patients Patients Individuals participating in the health care system for the purpose of receiving therapeutic, diagnostic, or preventive procedures. Clinician–Patient Relationship may present with petechiae Petechiae Primary Skin Lesions, gingival bleeding, epistaxis Epistaxis Bleeding from the nose. Granulomatosis with Polyangiitis, or menorrhagia. The diagnosis primarily depends on the clinical history and laboratory assays, including quantitative measurement of vWF, vWF ristocetin cofactor activity (vWF:RCo) assay, and FVIII coagulant assay. Management is based on the subtype of the disease. The most common agents used are desmopressin Desmopressin Hemophilia acetate and concentrates containing recombinant vWF and FVIII.
Last updated: May 17, 2024
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Von Willebrand disease (vWD) is a bleeding disorder caused by deficiency or dysfunction of the von Willebrand factor von Willebrand factor A high-molecular-weight plasma protein, produced by endothelial cells and megakaryocytes, that is part of the factor VIII/von Willebrand factor complex. The von Willebrand factor has receptors for collagen, platelets, and ristocetin activity as well as the immunologically distinct antigenic determinants. It functions in adhesion of platelets to collagen and hemostatic plug formation. The prolonged bleeding time in von Willebrand diseases is due to the deficiency of this factor. Hemostasis.
Type | Etiology | Pathologic mechanism | |
---|---|---|---|
Inherited | Type 1 Type 1 Spinal Muscular Atrophy | Autosomal dominant inheritance Autosomal dominant inheritance Autosomal Recessive and Autosomal Dominant Inheritance |
|
Type 2A | Autosomal dominant inheritance Autosomal dominant inheritance Autosomal Recessive and Autosomal Dominant Inheritance |
|
|
Type 2B | Autosomal dominant inheritance Autosomal dominant inheritance Autosomal Recessive and Autosomal Dominant Inheritance |
|
|
Type 2M | Autosomal dominant inheritance Autosomal dominant inheritance Autosomal Recessive and Autosomal Dominant Inheritance |
|
|
Type 2N | Autosomal recessive inheritance Autosomal recessive inheritance Autosomal Recessive and Autosomal Dominant Inheritance |
|
|
Type 3 Type 3 Spinal Muscular Atrophy | Autosomal recessive inheritance Autosomal recessive inheritance Autosomal Recessive and Autosomal Dominant Inheritance |
|
|
Acquired | Occurs secondary to other pathological processes | Several mechanisms have been proposed:
|
Clinical presentation varies and depends on the disease subtype. Presentation is mild or even asymptomatic in type 1 Type 1 Spinal Muscular Atrophy, with progressively increasing severity in types 2 and 3.
VWD should be suspected in individuals with an increased history of bleeding, positive family history Family History Adult Health Maintenance of vWD or increased bleeding, unexplained mild thrombocytopenia Mild Thrombocytopenia Thrombocytopenia, or unexplained mild prolongation of aPTT. Specific vWF and FVIII blood tests are needed to confirm the diagnosis.